Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
9 participants
INTERVENTIONAL
2007-10-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
NCT01376713
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
NCT01533948
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
NCT03754140
SBRT as a Vaccination for Metastatic Melanoma
NCT04042506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rituximab
rituximab
induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rituximab
induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Ocular melanoma
* Immunodeficiency syndromes or hypogammaglobulinaemia
* Active autoimmune diseases
* Treatment with immunosuppressive agents other than steroids
* Depressed bone marrow function (Leukopenia \<3000, platelet count \<100.000)
* Cardiac insufficiency NYHA (New York Heart Association) IV
* active Hepatitis B,C, or HIV infection
* Pregnancy or lactation
* Interstitial pulmonary disease
* Former treatment with anti-CD20 antibody
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephan N. Wagner, MD
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephan Wagner, MD
Role: PRINCIPAL_INVESTIGATOR
Med Univ Vienna
Alice Pinc, MD
Role: PRINCIPAL_INVESTIGATOR
Medical Univ Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Hospital Vienna, Dep. of Dermatology, Division of Immunology and Infectious Diseases
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIMM1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.